By Fineline Cube 
Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology Group Co., Ltd., has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. Key details, including the unit price, are yet to be disclosed.
MediTrust Health’s Mission
As China’s largest diversified healthcare payment platform, MediTrust Health is dedicated to addressing financing and payment challenges faced by patients, insurers, and pharmaceutical companies. The company aims to drive transformative changes in China’s healthcare payment system.
Core Products and Technology
MediTrust Health operates mind42.ai, a proprietary AI-powered decision-making platform, MediTrust Rx, a diversified medical supply chain payment platform, and MediTrust Healthcare, a commercial insurance physician network. These core products leverage AI technology to provide intelligent solutions for insurers, pharmaceutical firms, and patients.
Market Performance
As of December 31, 2024, MediTrust Health has served 1.6 million patients, 90+ insurers, and 140+ pharmaceutical companies. The company generated RMB 2.035 billion (USD 284 million) in revenue last year.-Fineline Info & Tech